Ken Griffin Summit Therapeutics Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 256,600 shares of SMMT stock, worth $5.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

256,600

Previous 239,000 7.36%

Holding current value

$5.09 Million

Previous $4.27 Million 16.01%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$16.65 - $23.76 $13.5 Million - $19.3 Million	811,333 Added 432.93%	998,740 $19.3 Million
Q4 2024 Feb 14, 2025	SELL	$17.52 - $23.46 $8.12 Million - $10.9 Million	-463,426 Reduced 71.21%	187,407 $3.35 Million
Q3 2024 Nov 14, 2024	BUY	$6.89 - $31.93 $4.48 Million - $20.8 Million	650,833 New	650,833 $14.3 Million
Q1 2024 May 15, 2024	BUY	$2.55 - $5.07 $12 - $25	5 New	5 $0
Q1 2023 May 15, 2023	SELL	$1.38 - $5.41 $35,875 - $140,643	-25,997 Reduced 53.74%	22,381 $39,000
Q4 2022 Feb 14, 2023	BUY	$0.68 - $5.31 $32,897 - $256,887	48,378 New	48,378 $205,000
Q2 2022 Aug 15, 2022	BUY	$0.92 - $2.38 $13,018 - $33,677	14,150 Added 33.22%	56,743 $57,000
Q4 2021 Feb 14, 2022	BUY	$2.45 - $5.64 $41,588 - $95,739	16,975 Added 66.26%	42,593 $114,000
Q2 2021 Aug 16, 2021	SELL	$5.15 - $8.46 $87,410 - $143,591	-16,973 Reduced 39.85%	25,618 $191,000
Q1 2021 May 17, 2021	BUY	$5.17 - $11.19 $136,596 - $295,650	26,421 Added 163.4%	42,591 $250,000
Q4 2020 Feb 16, 2021	BUY	$3.25 - $6.0 $52,552 - $97,020	16,170 New	16,170 $76,000

Others Institutions Holding SMMT

# of Institutions

236

Shares Held

86.8M

Call Options Held

1.84M

Put Options Held

3.13M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $3.99B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account